A new research agreement involving an Aberdeen biopharmaceutical company aims to accelerate the development of new therapeutics, underlining the strengths within North East Scotland’s life sciences cluster.
Elasmogen Ltd, a University of Aberdeen spin-out focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today (9 May 2017) announced a research collaboration with Amgen, to develop and deliver novel intracellular biologics. The collaboration combines the unique capabilities of Feldan’s Shuttle platform and Elasmogen’s soloMER™ technology to develop the delivery system and binding domains to two undisclosed intracellular targets for Amgen, one of the world’s leading independent biotechnology companies.